ArticleCirculation research2008
Chromogranin B regulates calcium signaling, nuclear factor kappaB activity, and brain natriuretic peptide production in cardiomyocytes.
Article in Circulation research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 73 citations in OpenAlex.
- Prediction of Major Adverse Cardiovascular Events in Peripheral Artery Disease: Integrating Metabolomics and Proteomics for Risk Stratification.Research (Washington, D.C.) · 2026Article
- Cardiac Localized Polycystin-2 in the Natriuretic Peptide Signaling Pathway and Hypertension.Journal of the American Society of Nephrology : JASN · 2025Article
- Chromogranin B Protects Human Umbilical Endothelial Cells against Oxidative Stress.International journal of molecular sciences · 2024Article
- A high-throughput drug screening identifies luteolin as a therapeutic candidate for pathological cardiac hypertrophy and heart failure.Frontiers in cardiovascular medicine · 2023Article
- Inositol 1,4,5-trisphosphate receptors in cardiomyocyte physiology and disease.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2022Review
- Biochemistry of the Endocrine Heart.Biology · 2022Review
- Spatio-temporal regulation of calpain activity after experimental myocardial infarction in vivo.Biochemistry and biophysics reports · 2021Article
- Chronic Naltrexone Therapy Is Associated with Improved Cardiac Function in Volume Overloaded Rats.Cardiovascular drugs and therapy · 2021Article
- Circulating Chromogranin B Is Associated With Left Ventricular Functional Recovery After Successful Recanalization of Chronic Total Occlusion.Frontiers in cardiovascular medicine · 2021Article
- Identification of potential crucial genes in atrial fibrillation: a bioinformatic analysis.BMC medical genomics · 2020Article
- Glycosylated Chromogranin A: Potential Role in the Pathogenesis of Heart Failure.Current heart failure reports · 2017Review
- Polycystin 2-dependent cardio-protective mechanisms revealed by cardiac stress.Pflugers Archiv : European journal of physiology · 2017Article
- Response to letter regarding article "Inositol 1,4,5-trisphosphate receptors and human left ventricular myocytes".Circulation · 2014Article
- A modified approach to induce predictable congestive heart failure by volume overload in rats.PloS one · 2014Article
- The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study.PloS one · 2013Article
- Secretogranin II; a protein increased in the myocardium and circulation in heart failure with cardioprotective properties.PloS one · 2012Article
- Tear me down: role of calpain in the development of cardiac ventricular hypertrophy.Circulation research · 2011Review
- Human catestatin peptides differentially regulate infarct size in the ischemic-reperfused rat heart.Regulatory peptides · 2010Article
- Inositol 1,4,5-trisphosphate receptor in chromaffin secretory granules and its relation to chromogranins.Cellular and molecular neurobiology · 2010Review
- Paclitaxel accelerates spontaneous calcium oscillations in cardiomyocytes by interacting with NCS-1 and the InsP3R.Journal of molecular and cellular cardiology · 2010Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Altered regulation of signaling pathways can lead to pathologies including cardiac hypertrophy and heart failure. We report that neonatal and adult cardiomyocytes express chromogranin B (CGB), a Ca(2+) binding protein that modulates Ca(2+) release by the inositol 1,4,5-trisphosphate receptor (InsP(3)R). Using fluorescent Ca(2+) indicator dyes, we found that CGB regulates InsP(3)-dependent Ca(2+) release in response to angiotensin II, an octapeptide hormone that promotes cardiac hypertrophy. ELISA experiments and luciferase reporter assays identified angiotensin II as a potent inducer of brain natriuretic peptide (BNP), a hormone that recently emerged as an important biomarker in cardiovascular disease. CGB was found to regulate angiotensin II-stimulated and basal secretion, expression and promoter activity of BNP that depend on the InsP(3)R. Moreover, we provide evidence that CGB acts via the transcription activity of nuclear factor kappaB in an InsP(3)/Ca(2+)-dependent manner but independent of nuclear factor of activated T cells. In vivo experiments further showed that cardiac hypertrophy induced by angiotensin II, a condition characterized by increased ventricular BNP production, is associated with upregulation of ventricular CGB expression. Overexpression of CGB in cardiomyocytes, in turn, induced the BNP promoter. The evidence presented in this study identifies CGB as a novel regulator of cardiomyocyte InsP(3)/Ca(2+)-dependent signaling, nuclear factor kappaB activity, and BNP production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.